{"product_id":"ebmedical-five-forces-analysis","title":"Eyebright Medical Technology Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEyebright Medical Technology faces moderate supplier leverage, evolving buyer expectations, and rising competitive intensity from both incumbent medtech firms and agile startups, while regulatory hurdles and substitute treatments shape market dynamics.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Eyebright Medical Technology’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized raw material reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyebright depends on high-purity medical-grade polymers and optical materials for intraocular and contact lenses; about 70–80% of key monomers are supplied by three global chemical giants, raising supplier leverage.\u003c\/p\u003e\n\u003cp\u003eThese suppliers command pricing power—raw polymer costs rose ~12% in 2024—while ophthalmic specs force extensive re-validation (often 6–12 months), making supplier switching costly and slow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent quality and regulatory standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of medical-grade components must hold ISO 13485 and NMPA approvals, narrowing qualified vendors to an estimated 12–15% of global suppliers; this reduces competition and raises supplier leverage. \u003c\/p\u003e\n\u003cp\u003eHigh certification costs (average \u0026gt;$150k setup plus annual audits) create a strong barrier to entry, strengthening existing suppliers’ pricing power. \u003c\/p\u003e\n\u003cp\u003eEyebright needs multi‑year contracts and dual sourcing with certified partners to secure quality, control supply risk, and meet regulatory audits. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological exclusivity of components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProprietary high-precision manufacturing tools are concentrated among ~5 specialist firms; in 2024 these suppliers raised capital equipment prices ~8–12%, squeezing margins for device makers. If Eyebright faces a 6–12 week delay or a 10–15% capex rise due to supplier prioritization, annual production volume could fall ~7–10% and gross margin drop 150–400 bps. This tech dependence gives suppliers strong leverage over pricing and lead times.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical integration trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyebright self-develops some materials but outsources key components to specialists; in 2025 about 62% of BOM costs remain purchased, limiting supplier leverage.\u003c\/p\u003e\n\u003cp\u003eUpstream consolidation and suppliers moving into assembly are pressuring device margins—medical supply M\u0026amp;A rose 18% in 2024, tightening inputs.\u003c\/p\u003e\n\u003cp\u003eNegotiation power ties to Eyebright’s purchase volumes and R\u0026amp;D: if in-house material share rises from 38% to 55% by 2027, gross margin could widen ~240 bps.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of BOM outsourced (2025)\u003c\/li\u003e\n\u003cli\u003e18% rise in supplier M\u0026amp;A (2024)\u003c\/li\u003e\n\u003cli\u003eTarget 55% in-house materials by 2027 → ~240 bps margin gain\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh switching costs for specialized inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChanging a primary supplier for a medical device often requires new clinical trials or regulatory filings to confirm biocompatibility and safety, which can take 12–36 months and cost $1–5M per study, so Eyebright is unlikely to switch vendors if input prices rise.\u003c\/p\u003e\n\u003cp\u003eThis lock-in raises supplier power: established suppliers of critical inputs can exert pricing leverage and contract terms, shifting margin risk onto Eyebright; in 2024, specialty biomaterial suppliers reported average gross margins of ~38%, underscoring pricing strength.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12–36 months and $1–5M per validation\u003c\/li\u003e\n\u003cli\u003eHigh supplier gross margins (~38% in 2024)\u003c\/li\u003e\n\u003cli\u003eSwitching risk: regulatory + clinical + capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: concentrated monomers, long costly switches, margin risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong leverage: 70–80% key monomers from three giants, 62% BOM outsourced (2025), ISO 13485\/NMPA limits qualified vendors to ~12–15%, and switching needs 12–36 months and $1–5M; polymer costs rose ~12% in 2024 and specialist tool prices +8–12%, risking 7–10% volume loss and 150–400 bps margin hit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey monomer share\u003c\/td\u003e\n\u003ctd\u003e70–80% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBOM outsourced\u003c\/td\u003e\n\u003ctd\u003e62% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified vendors\u003c\/td\u003e\n\u003ctd\u003e12–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolymer cost change\u003c\/td\u003e\n\u003ctd\u003e+12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation time\/cost\u003c\/td\u003e\n\u003ctd\u003e12–36m \/ $1–5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Eyebright Medical Technology, this Porter's Five Forces overview uncovers key competitive drivers, supplier and buyer power, entry barriers, substitute threats, and disruptive risks shaping its pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Eyebright Medical Technology—ideal for quick strategic assessment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated purchasing power of hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic and private hospitals are Eyebright Medical Technology’s main buyers, and in 2024 the top 20 hospital networks accounted for roughly 38% of national device procurement, concentrating buying power. Large groups use centralized tenders to win volume discounts of 15–30% and extend payment terms to 60–90 days, squeezing supplier margins. That concentration forces manufacturers to bid aggressively on price to secure multi-year contracts worth millions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of centralized volume-based procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn China, government volume-based procurement (VBP) now commands ~60–80% of on-premise drug volumes in pilot provinces, sharply boosting state bargaining power and forcing price cuts of 30–70% in some tenders by 2024.\u003c\/p\u003e\n\u003cp\u003eBy aggregating demand across provinces, Beijing secures guaranteed market share in exchange for steep price ceilings, squeezing margins for medtech firms like Eyebright Medical Technology.\u003c\/p\u003e\n\u003cp\u003eEyebright must offset mandated price declines—examples show median gross-margin compression of 8–15 percentage points—by driving cost innovation: local sourcing, process automation, and SKU rationalization to protect profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow switching costs for standardized devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLow switching costs for standardized devices mean ophthalmologists can move between reputable brands easily; surveys show 64% of hospital procurement teams prioritize price for common intraocular lenses (IOLs) and instruments, and a 2024 HealthTech report found 18% annual vendor churn in ophthalmic consumables. If a rival matches clinical outcomes at lower prices, purchasing committees often switch, so Eyebright faces pressure to sustain brand loyalty and clear clinical differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice sensitivity in the private consumer market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEyebright’s consumer products like orthokeratology lenses are largely paid out-of-pocket, so middle-class households—who account for ~60% of urban eyewear spend in China (2024)—show high price sensitivity; a 10–15% price rise risks switching to cheaper local lenses or soft-contact alternatives.\u003c\/p\u003e\n\u003cp\u003eThis constrains Eyebright from passing through higher manufacturing costs; gross-margin pressure must be managed via cost cuts or value-added services instead.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% urban consumer share (China, 2024)\u003c\/li\u003e\n\u003cli\u003e10–15% price rise → higher churn risk\u003c\/li\u003e\n\u003cli\u003eOut-of-pocket payments limit price pass-through\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformation transparency and clinical evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern hospitals access large clinical databases and meta-analyses; 68% of procurement decisions in EU hospitals (2024 EU HealthProcure survey) require head-to-head evidence versus incumbents, so buyers are highly informed.\u003c\/p\u003e\n\u003cp\u003eClinicians demand randomized controlled trials or real-world evidence showing superior safety or cost-per-QALY; lacking this, Eyebright faces displacement by established international brands.\u003c\/p\u003e\n\u003cp\u003eThis data requirement increases buyer leverage, forcing Eyebright to invest in costly trials and price concessions to win adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% EU hospitals require head-to-head evidence (2024)\u003c\/li\u003e\n\u003cli\u003eRCTs or real-world evidence drive procurement\u003c\/li\u003e\n\u003cli\u003eHigher trial costs raise price\/negotiation pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ leverage crushes margins: 30–70% VBP cuts, 15–30% tender discounts, 8–15ppt hit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (hospitals, VBP, consumers) hold strong leverage: top 20 hospitals = 38% procurement (2024), VBP drives 30–70% price cuts, hospital tenders yield 15–30% discounts and 60–90 day terms, consumer urban spend ~60% (China, 2024) with 10–15% churn risk on price rises, 68% EU hospitals require head-to-head evidence (2024), median gross-margin hit 8–15 ppt.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-20 hospital share\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP price cuts\u003c\/td\u003e\n\u003ctd\u003e30–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital discounts\u003c\/td\u003e\n\u003ctd\u003e15–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayment terms\u003c\/td\u003e\n\u003ctd\u003e60–90 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrban consumer share (China)\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice rise churn risk\u003c\/td\u003e\n\u003ctd\u003e10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU head-to-head requirement\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-margin compression\u003c\/td\u003e\n\u003ctd\u003e8–15 ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eEyebright Medical Technology Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Eyebright Medical Technology Porter’s Five Forces analysis you’ll receive immediately after purchase—fully formatted, professional, and ready for download with no placeholders or mockups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747607327097,"sku":"ebmedical-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ebmedical-five-forces-analysis.png?v=1772200269","url":"https:\/\/matrixbcg.com\/products\/ebmedical-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}